Bhavna Oza

Bhavna Oza

Auto-generated profile, based on publicly available information

Bhavna Oza

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Contemporary Clinical Trials
Verified
Journal Article
Open access
BOBhavna Oza
Bhavna Oza
EFEleni Frangou
Eleni Frangou
BSBen Smith
Ben Smith
HBHanna Bryant
Hanna Bryant
RKRick Kaplan
Rick Kaplan
AMAngela Meade
Angela Meade
20–60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting. RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research questions may be addressed over time. The target population is patients with histologically proven resected locally advanced RCC (clear cell and non-clear cell histological subtypes), with no residual macroscopic disease, who are at high or intermediate risk of relapse (Leibovich score 3–11). Patients with fully resected synchronous ipsilateral adrenal metastases are included. Participants are randomly assigned (3,2:2) to Arm A - active monitoring (no placebo) for one year, Arm B - durvalumab (PD-L1 inhibitor) 4-weekly for one year; or Arm C - combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles. The co-primary outcomes are disease-free-survival (DFS) and overall survival (OS). Secondary outcomes include safety, metastasis-free survival, RCC specific survival, quality of life, and patient and clinician preferences. Tumour tissue, plasma and urine are collected for molecular analysis (TransRAMPART). ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017–002329-39, CTA #: 20363/0380/001–0001, MREC #: 17/LO/1875, ClinicalTrials.gov Identifier: NCT03288532, RAMPART grant number: MC_UU_12023/25, TransRAMPART grant number: A28690 Cancer Research UK, RAMPART Protocol version 5.0.

25 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
BOBhavna Oza
Bhavna Oza
TETim Eisen
Tim Eisen
EFEleni Frangou
Eleni Frangou
GSGrant D Stewart
Grant D Stewart
ABAxel Bex
Axel Bex
AMAngela Meade
Angela Meade
PURPOSE: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC. METHODS: Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non–clear-cell subtype, papillary, and chromophobe carcinomas. RESULTS: Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non–clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC. CONCLUSION: The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non–clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.

1 September 2021 in Contemporary Clinical Trials
Verified
Journal Article
Open access
AMAngela Meade
Angela Meade
BOBhavna Oza
Bhavna Oza
EFEleni Frangou
Eleni Frangou
BSBen Smith
Ben Smith
HBHanna Bryant
Hanna Bryant
MPMahesh K.B. Parmar
Mahesh K.B. Parmar
The development of therapeutics in oncology is a highly active research area for the pharmaceutical and biotechnology industries, but also has a strong academic base. Many new agents have been developed in recent years, most with specific biological targets. This has mandated the need to look at different ways to streamline the evaluation of new agents. One solution has been the development of adaptive trial designs that allow the evaluation of multiple agents, concentrating on the most promising agents while screening out those which are unlikely to benefit patients. Another way forward has been the growth of partnerships between academia and industry with the shared goal of designing and conducting high quality clinical trials which answer important clinical questions as efficiently as possible. The RAMPART trial (NCT03288532) brings together both of these processes in an attempt to improve outcomes for patients with locally advanced renal cell carcinoma (RCC), where no globally acceptable adjuvant strategy after nephrectomy currently exist. RAMPART is led by the MRC CTU at University College London (UCL), in collaboration with other international academic groups and industry. We aim to facilitate the use of data from RAMPART, (dependent on outcomes), for a future regulatory submission that will extend the license of the agents being investigated. We share our experience in order to lay the foundations for an effective trial design and conduct framework and to guide others who may be considering similar collaborations. Trial Registration: ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017-002329-39. CTA #: 20363/0380/001-0001. MREC #: 17/LO/1875. ClinicalTrials.gov Identifier: NCT03288532 RAMPART grant number: MC_UU_12023/25. . RAMPART Protocol version 5.0.

26 July 2025 in European Urology Open Science
Verified
Journal Article
Open access
BOBhavna Oza
Bhavna Oza
EFEleni Frangou
Eleni Frangou
TETim Eisen
Tim Eisen
GSGrant D. Stewart
Grant D. Stewart
ABAxel Bex
Axel Bex
AMAngela Meade
Angela Meade
Outcomes after nephrectomy for intermediate- and high-risk renal cell carcinoma (RCC) according to histological subtype are poorly characterised. This study aims to determine the value of RCC histology in predicting survival and to inform on surveillance strategies in relation to patterns of first recurrence. We pooled data from phase 3 trials: SORCE (n = 1689) and ASSURE (n = 1853). Of 3542 patients, 2881 had clear-cell RCC (ccRCC), 269 had papillary RCC (pRCC), 201 had chromophobe RCC (chRCC), and 191 had sarcomatoid RCC (sRCC). Relapse rates, median time to relapse (TTR), and first relapse sites were reported. Multivariable Cox regression models evaluated overall survival by histology, adjusting for initial relapse location and other important clinical factors. Patients with pRCC and ccRCC had similar overall survival (log-rank p = 0.1). The median TTR for those with pRCC was 1.34 yr (interquartile range [IQR] 0.76, 2.59) compared with 1.78 yr (IQR 0.96, 3.38) for ccRCC patients (p = 0.012). Patients with chRCC had a median TTR of 2.72 yr (IQR 0.91, 4.11), and those with sRCC had a median TTR of 0.74 yr (IQR 0.50, 1.55). For sRCC patients, relapsing in the chest was associated with a lower risk of death than those relapsing in the abdomen (hazard ratio [HR] 0.5, confidence interval [CI]: 0.3, 0.88; p = 0.06). A similar trend was shown for pRCC (HR 0.5, CI: 0.2, 1.3; p = 0.1). Recurrence patterns for World Health Organization 2020 molecularly classified RCCs were not included. Despite pooling phase three datasets, small event numbers led to imprecise estimates, particularly for chRCC. Patients with intermediate and high-risk pRCC relapse earlier than those with ccRCC. Papillary RCC and sRCC first recurring in the abdomen exhibit poor prognosis, warranting consideration of additional abdominal imaging to enhance early relapse detection. ChRCC exhibits favourable prognosis and could avoid image-based surveillance until year 2. This study evaluates pooled data from large phase 3 trials to precisely delineate relapse patterns for patients with intermediate- and high-risk cell renal cell carcinoma (RCC) according to their histology. The site and timing of first relapse provide useful information to support histology-specific RCC surveillance after nephrectomy. Development of genetic and molecular signatures corresponding to relapses at poor prognosis sites for each histology will individualise follow-up and is the next step.

20 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BOBhavna Oza
Bhavna Oza
TETim Eisen
Tim Eisen
GSGrant D Stewart
Grant D Stewart
ABAxel Bex
Axel Bex
PRPatrick Royston
Patrick Royston
AMAngela Meade
Angela Meade